公开(公告)号：US20020165178A1

公开(公告)日：2002-11-07

申请号：US09895007

申请日：2001-06-28

Inventor： Christian Schetter ,  Robert L. Bratzler ,  Deanna M. Petersen

IPC: A61K048/00 ,  C07H021/04

CPC classification number: A61K38/1816 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7125 ,  A61K38/00 ,  A61K38/193 ,  A61K38/196 ,  A61K2300/00

Abstract: The invention involves administration of an immunostimulatory nucleic acid alone or in combination with an anemia, thrombocytopenia, or neutropenia medicament for the treatment or prevention of anemia, thrombocytopenia, and neutropenia in subjects. The agents in combination are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of immunostimulatory nucleic acids and anemia, thrombocytopenia, or neutropenia drugs.

Abstract translation: 本发明涉及单独或与贫血，血小板减少症或嗜中性白细胞减少症药物组合施用免疫刺激性核酸，用于治疗或预防受试者中的贫血，血小板减少症和中性粒细胞减少症。 组合的药剂以协同量或以各种剂量或各种时间表进行施用。 本发明还涉及关于免疫刺激性核酸与贫血，血小板减少症或中性白细胞减少症药物的组合的试剂盒和组合物。

公开(公告)号：US20020114796A1

公开(公告)日：2002-08-22

申请号：US09998575

申请日：2001-11-16

Inventor： Johann Eibl

IPC: A61K038/48 ,  A61K038/53

CPC classification number: A61K45/06 ,  A61K35/12 ,  A61K38/196 ,  A61K38/363 ,  A61K38/39 ,  A61K38/4833 ,  A61K38/57 ,  A61K38/45 ,  A61K2300/00

Abstract: The invention relates to a medicament for topical application for the purpose of stopping bleeding and/or closing wounds and/or promoting wound healing, which as active substances nullproduced conventionally of allogenic plasma or tissue or recombinantlynullcontains fibrinogen or fibrin, thrombin and one or several tranglutaminase(s), wherein the medicament, as a further active substance, contains one or several protease inhibitor(s) selected from the group consisting of serpins that do not have inhibiting effects on collagenases and elastases, all of the active substances being of allogenic origin and having been subjected to a process for virus depletion and/or virus inactivation, with the proviso that the virus inactivtion of the one or several protease inhibitor(s) has not been carried out in the presence of the other active substances.

Abstract translation: 本发明涉及用于局部应用以止血和/或闭合伤口和/或促进伤口愈合的药物，其作为常规产生的同种异体血浆或组织的活性物质或重组含有纤维蛋白原或纤维蛋白，凝血酶和一种 或多种转谷氨酰胺酶，其中作为另外的活性物质的药物含有一种或几种蛋白酶抑制剂，其选自对胶原酶和弹性蛋白酶不具有抑制作用的丝氨酸蛋白酶，所有活性物质均为 的同种异体来源并已经经历病毒消耗和/或病毒灭活的过程，条件是一种或几种蛋白酶抑制剂的病毒灭活尚未在其它活性物质的存在下进行。

公开(公告)号：US6013067A

公开(公告)日：2000-01-11

申请号：US482212

申请日：1995-06-07

Applicant: Willem E. Fibbe ,  Angelika Grossman

Inventor： Willem E. Fibbe ,  Angelika Grossman

IPC: A61K38/00 ,  A61K35/14 ,  A61K35/28 ,  A61K38/19 ,  A61P7/00 ,  A61P43/00 ,  A61M31/00

CPC classification number: A61K35/28 ,  A61K38/196

Abstract: Methods for increasing hematopoietic cells, including platelets and erythrocytes, in patients receiving bone marrow or peripheral blood stem cell transplants are disclosed. The methods comprise administering to a donor an amount of thrombopoietin sufficient to stimulate proliferation of cells of the myeloid lineage, collecting cells from the donor, and administering the collected cells to a recipient patient. The recipient patient may be treated with additional thrombopoietin. The methods are useful within allogeneic and autologous transplantation procedures.

Abstract translation: 公开了在接受骨髓或外周血干细胞移植的患者中增加造血细胞（包括血小板和红细胞）的方法。 所述方法包括向供体施用足以刺激骨髓谱系细胞增殖的量的血小板生成素，从供体收集细胞，以及将收集的细胞施用于受体患者。 受体患者可以用额外的血小板生成素治疗。 这些方法在同种异体和自体移植手术中是有用的。

公开(公告)号：US20240024479A1

公开(公告)日：2024-01-25

申请号：US18480306

申请日：2023-10-03

Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services

Inventor： Richard W. Childs ,  David S.J. Allan

IPC: A61K39/00 ,  C07K14/715 ,  C07K14/705 ,  C07K14/735 ,  A61P35/00 ,  A61K38/19 ,  A61K31/4152 ,  A61K38/20 ,  A61K45/06

CPC classification number: A61K39/4637 ,  C07K14/715 ,  C07K14/7155 ,  C07K14/7156 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70535 ,  C07K14/7056 ,  C07K14/70503 ,  A61K39/4611 ,  A61K39/4613 ,  A61P35/00 ,  A61K38/196 ,  A61K31/4152 ,  A61K38/2013 ,  A61K45/06 ,  C07K2319/02 ,  C07K2319/03

Abstract: Modified natural killer (NK) or T cells expressing hematopoietic growth factor receptors are provided. In some aspects, the modified NK cells or T cells express a thrombopoietin receptor, an erythropoietin receptor, or a chimeric polypeptide including an extracellular domain of a thrombopoietin receptor, a transmembrane domain, and an intracellular domain including an interleukin-2 receptor beta intracellular signaling domain. Methods of treating a subject with cancer are also provided, including administering the modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or erythropoietin receptor agonist, and in some example, interleukin-2, particularly reduced or low-dose amounts of IL-2.

公开(公告)号：US20180303838A1

公开(公告)日：2018-10-25

申请号：US15839685

申请日：2017-12-12

Applicant: G1 Therapeutics, Inc.

Inventor： Jay Copeland Strum ,  John Emerson Bisi ,  Patrick Joseph Roberts ,  Francis Xavier Tavares

IPC: A61K31/527 ,  C07D487/20 ,  A61K45/06 ,  A61K38/20 ,  A61K38/18 ,  A61K38/19 ,  A61K31/202 ,  A61K31/702 ,  A61N5/10 ,  A61K31/519

CPC classification number: A61K31/527 ,  A61K31/202 ,  A61K31/519 ,  A61K31/702 ,  A61K38/18 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/196 ,  A61K38/208 ,  A61K45/06 ,  A61N5/10 ,  A61N2005/1094 ,  C07D487/20 ,  A61K2300/00

Abstract: This invention is in the area of improved compounds and methods for transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC), from the damage associated with ionizing radiation (IR) exposure using selective radioprotectants.

公开(公告)号：US20160067301A1

公开(公告)日：2016-03-10

申请号：US14783789

申请日：2014-04-10

Applicant: Nan WANG ,  Alan R. TALL

Inventor： Nan WANG ,  Alan R. TALL

IPC: A61K38/05 ,  A61K31/4355 ,  A61K31/506 ,  A61K31/404 ,  A61K31/496 ,  A61K38/19

CPC classification number: A61K38/05 ,  A61K31/404 ,  A61K31/4152 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/496 ,  A61K31/506 ,  A61K38/196 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention provides a method of treating a subject to increase the subject's platelet count which comprises administering to the subject an amount of one or more of an antagonist or inhibitor of ABCG4, Lyn kinase or c-CBL effective to antagonize or inhibit such ABCG4, Lyn kinase or c-CBL so as to thereby increase the subject's platelet count.

Abstract translation: 本发明提供了治疗受试者增加受试者血小板计数的方法，其包括向受试者施用一定量的一种或多种拮抗或抑制这种ABCG4的ABCG4拮抗剂或抑制剂，Lyn激酶或c-CBL， Lyn激酶或c-CBL，从而增加受试者的血小板计数。

公开(公告)号：US20150231178A1

公开(公告)日：2015-08-20

申请号：US14498605

申请日：2014-09-26

Applicant: M. Rigdon Lentz

Inventor： M. Rigdon Lentz

IPC: A61K35/14 ,  A61N5/10 ,  A61M1/36 ,  A61K35/16 ,  A61K31/454

CPC classification number: A61K35/14 ,  A61K31/00 ,  A61K31/337 ,  A61K31/454 ,  A61K31/555 ,  A61K31/704 ,  A61K35/16 ,  A61K38/18 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/196 ,  A61K41/00 ,  A61K41/0019 ,  A61M1/34 ,  A61M1/342 ,  A61M1/3441 ,  A61M1/3472 ,  A61M1/3482 ,  A61M1/3603 ,  A61M1/3681 ,  A61M2202/0417 ,  A61M2205/50 ,  A61M2205/75 ,  A61N5/10 ,  A61N5/1028 ,  B01D15/00 ,  B01D29/50 ,  B01D37/00 ,  B01D61/02 ,  A61K2300/00

Abstract: A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF. This provides a basis for an improved effect when combined with any treatment that enhances cytokine activity against the tumors, for example, treatments using alkylating agents, doxyrubicin, carboplatinum, cisplatinum, and taxol. Alternatively, the ultrapheresis treatment can be combined with local chemotherapy, systemic chemotherapy, and/or radiation.

Abstract translation: 一种治疗癌症的方法是使用超级血液分离法，精制以除去小于120,000道尔顿分子量的化合物，然后施用替代液，以刺激患者的免疫系统攻击实体瘤。 在优选实施例中，使用孔径为0.02至0.05微米，分子量截留值为120,000道尔顿的毛细管超滤器将患者超薄，足以过滤一个血液体积。 优选的替代液体是超分离的正常血浆。 患者优选每天治疗三周，进行诊断测试以证实肿瘤已经收缩，然后重复治疗方案。 治疗优选与替代疗法组合，例如用抗血管生成化合物，一种或多种细胞因子如TNF，γ干扰素或IL-2或促凝血剂化合物的治疗。 治疗增加内源性，局部水平的细胞因子，如TNF。 当提供增强细胞因子对肿瘤活性的治疗，例如使用烷化剂，多柔比星，卡铂，顺铂和紫杉醇的治疗时，这提供了改善效果的基础。 或者，超单位治疗可以与局部化疗，全身化学疗法和/或辐射结合。

公开(公告)号：US08980329B2

公开(公告)日：2015-03-17

申请号：US12875022

申请日：2010-09-02

Applicant: Janice Marie Brown

Inventor： Janice Marie Brown

IPC: A61K35/26 ,  C12N5/00 ,  C12N5/08 ,  C12N5/02 ,  A61K38/19 ,  A61K38/18

CPC classification number: A61K35/15 ,  A61K35/19 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/196 ,  A61K2300/00

Abstract: Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed in the absence of HLA typing, and the cells may be mismatched at one or more Class I HLA loci. The transplantation may provide for treatment of ongoing disease, or prevention of disease in high risk patients.

Abstract translation: 通过移植或输注同种异体骨髓祖细胞（包括CMP，GMP，MEP和MKP细胞亚群）增强骨髓功能。 骨髓祖细胞改善贫血和血小板减少症的后遗症，并可预防或治疗与化疗，放疗等相关的胃肠道粘膜炎。 可以在不存在HLA分型的情况下进行移植或输注，并且细胞可能在一个或多个I类HLA基因座处不匹配。 该移植可以提供治疗正在进行的疾病或预防高危患者的疾病。

公开(公告)号：US20150031623A1

公开(公告)日：2015-01-29

申请号：US14348147

申请日：2011-09-29

Applicant: John E. Baker

Inventor： John E. Baker

IPC: A61K38/19

CPC classification number: C07K16/26 ,  A61K9/0019 ,  A61K31/4152 ,  A61K38/196 ,  A61K38/22 ,  C07K2317/41

Abstract: The present invention provides therapeutic modalities for the treatment of an ischemic event (e.g., stroke) that creates or embodies a risk of neurological damage in CNS sites by administration of a thrombopoietin receptor ligand.

Abstract translation: 本发明提供治疗通过施用血小板生成素受体配体产生或体现CNS位点神经损伤风险的缺血事件（例如中风）的治疗方式。

公开(公告)号：US20140286962A1

公开(公告)日：2014-09-25

申请号：US14219218

申请日：2014-03-19

Applicant: ALEXION PHARMACEUTICALS, INC.

Inventor： Mayur MOVALIA ,  Andrea ILLINGWORTH ,  Susan FAAS MCKNIGHT ,  Russell P. ROTHER

IPC: G01N33/50 ,  A61K31/727 ,  C07K16/40 ,  A61K31/56 ,  A61K38/19 ,  A61K38/48 ,  A61K31/352 ,  A61K35/14

CPC classification number: G01N33/5094 ,  A61K31/352 ,  A61K31/56 ,  A61K31/727 ,  A61K35/19 ,  A61K38/196 ,  A61K38/4886 ,  C07K16/40 ,  G01N33/56972 ,  G01N33/6893 ,  G01N2800/226

Abstract: The disclosure relates to methods for detecting PNH Type II cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of PNH Type II cells in the patient's blood. The disclosure also features reagents and conjugates for use in the methods.

Abstract translation: 本公开涉及用于检测生物样品中PNH II型细胞群的方法，以及用于基于患者血液中PNH II型细胞的百分比来确定患者是否处于发生血小板减少症或血栓形成的风险增加的方法。 本公开还涉及用于该方法的试剂和共轭物。